The biotech sector faces uncertainty amid fluctuating tax policies, tariffs, and interest rates, impacting investment and growth as noted by EY analysts. HHS cancellations of biotech grants tied to non-U.S. funding raise industry concerns over international investment. FDA leadership emphasizes modernization, AI integration, and expedited regulatory pathways to accelerate innovation. Meanwhile, the U.K. blocks Alzheimer’s drugs from national coverage due to cost and benefit assessments. Pharmaceutical marketing teams wrestle with tightening budgets and heightened demands, navigating digital content production challenges.